May. 16 at 1:45 AM
$CPHI 10Q is out! 3/31/26 Revenue of
$983,536 compared to 3/31/26
$1,136,287. Net loss of
$1,143,148 compared to NL of
$785,572 in Q1 '25.
Working capital was <5,264,123> with
$2,003,555 in current assets and
$7,267,678 in current liabilities.
Equity increased from
$22,739,572 at Q1 2025 to
$37,024,190 in Q1 2026 as more intangibles were recorded in February 2026. The Xiaoyum Chen agreement for "Topiroxostat Nano Emulsion" and the Xiaoyan Zhang agreement for Prinsepia Utilis Esterol Tablets.
The accumulated deficit was
$48,357,383. Must have ass-kicker of tax loss carry forward/back!
